analysis

Anthos Therapeutics Shares New Analysis from the Landmark AZALEA-TIMI 71 Study Demonstrating the Factor XI Inhibitor Abelacimab Substantially Reduced Bleeding in Patients on Antiplatelet Therapy Compared to Rivaroxaban

November 16, 2024 16:38 ET | Source: Anthos Therapeutics Data presented at the American Heart Association Scientific Sessions show a…

4 days ago

Anthos Therapeutics Shares New Analysis from the Landmark AZALEA-TIMI 71 Study Demonstrating the Factor XI Inhibitor Abelacimab Substantially Reduced Bleeding in Patients on Antiplatelet Therapy Compared to Rivaroxaban

November 16, 2024 16:38 ET | Source: Anthos Therapeutics Data presented at the American Heart Association Scientific Sessions show a…

5 days ago

WorldInvest.org Enhances Trading Experience with Expert Analysis Team to Guide Market Decisions

New York, NY, Nov. 11, 2024 (GLOBE NEWSWIRE) -- WorldInvest.org Strengthens Market Insights for Traders with Dedicated Analysis Team. WorldInvest.org,…

1 week ago